Comparison of whole-body diffusion-weighted magnetic resonance and FDG-PET/CT in the assessment of Hodgkin's lymphoma for staging and treatment response

Juan Montoro, Daniele Laszlo, Natalia Pin Chuen Zing, Giuseppe Petralia, Giorgio Conte, Marzia Colandrea, Giovanni Martinelli, Lorenzo Preda, Juan Montoro, Daniele Laszlo, Natalia Pin Chuen Zing, Giuseppe Petralia, Giorgio Conte, Marzia Colandrea, Giovanni Martinelli, Lorenzo Preda

Abstract

Computed tomography (CT), 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), and hybrid FDG-PET/CT are the most commonly used diagnostic tools for the initial staging and treatment response assessment of lymphomas [1]. The aim of this report is to compare the correlations between functional imaging markers derived from FDG-PET/CT and whole-body, diffusion-weighted magnetic resonance imaging (DW-MRI) in a young patient affected by Hodgkin's lymphoma (HL).

Keywords: Hodgkin’s lymphoma; PET/CT; whole-body diffusion-weighted magnetic resonance.

Figures

Figure 1:. (a) Coronal maximum intensity projection…
Figure 1:. (a) Coronal maximum intensity projection (MIP) FDG-PET/CT performed at initial staging showing right axillary, bilateral cervical, mediastinal, lombo-aortic and pelvic lymph node involvement, multiple hepatic lesions, splenomegaly, humeral, vertebral, and pelvic bone marrow involvement. (b) Coronal, whole-body, grayscale inverted MIP DW-MRI performed at initial staging showing extensive disease with the same distributions as FDG-PET/CT.
Figure 2:. (a) Coronal MIP FDG-PET/CT performed…
Figure 2:. (a) Coronal MIP FDG-PET/CT performed six months after treatment demonstrating the absence of any residual abnormal activity. (b) Post-treatment coronal, whole-body grayscale inverted MIP DW-MRI showing no nodal or extranodalresidual disease.

References

    1. Vermoolen MA, et al. Magnetic resonance imaging of malignant lymphoma. Expert Rev Hematol. 2011;4:161–71. doi: 10.1586/ehm.11.17.
    1. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009;50:1257–60. doi: 10.1080/10428190903040048.
    1. Jerusalem G, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica. 2001;86:266–73.
    1. Cheson BD, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86. doi: 10.1200/JCO.2006.09.2403.
    1. Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood. 2008;111:504–16. doi: 10.1182/blood-2007-07-101899.
    1. Wu X, et al. Correlations between functional Imaging markers derived from PET/CT and diffusion-weighted MRI in diffuse large B-cell lymphoma and follicular lymphoma. PLoS One. 2014;15(9):e84999. doi: 10.1371/journal.pone.0084999.
    1. Herman M, et al. Comparison of magnetic resonance imaging and (67)gallium scintigraphy in the evaluation of posttherapeutic residual mediastinal mass in the patients with Hodgkin’s lymphoma. Eur J Radiol. 2007;64:432–8. doi: 10.1016/j.ejrad.2007.03.003.
    1. Marzolini M, et al. Diffusion-weighted MRI compared to FDG PET-CT in the staging and response assessment of Hodgkin’s lymphoma. Br J Haematol. 2012;156:557. doi: 10.1111/j.1365-2141.2011.08959.x.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe